ITRM Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Iterum Therapeutics PLC (ITRM) is not a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock faces significant challenges, including potential delisting from Nasdaq, a distressed valuation, and the need to raise capital in the near future. Technical indicators are bearish, and there are no positive trading signals or catalysts to suggest a turnaround. The financials show improvement in net income but remain negative overall, with declining EPS and stagnant revenue growth. Analysts have downgraded the stock, and there is no recent activity from Congress or influential figures to suggest confidence in the stock.
The technical indicators are bearish. The MACD is negative and expanding downward, RSI is neutral at 32.094, and moving averages indicate a bearish trend (SMA_200 > SMA_20 > SMA_5). The stock is trading below key support levels, with a pivot at 0.217 and current pre-market price at 0.1663, suggesting further downside potential.
NULL identified. No positive trading signals or news catalysts are present.
The stock is at risk of being delisted from Nasdaq due to non-compliance with listing requirements. The company needs to raise capital in Q2 2026, which could be challenging given its distressed valuation. Analysts have downgraded the stock, citing these risks.
In 2025/Q3, revenue remained stagnant at $390,000 (0.00% YoY growth). Net income improved by 47.34% YoY but remains negative at -$8,979,000. EPS declined by -33.33% YoY to -0.2, and gross margin showed no growth at 5.38%. Overall, the financials indicate a struggling company with no clear growth trajectory.
On 2026-03-04, Maxim analyst Jason McCarthy downgraded Iterum Therapeutics to Hold from Buy, citing risks of delisting and the need for capital raising. The analyst notes the company's distressed valuation and challenging outlook.
